Tenaya Therapeutics, Inc. · NASDAQ:TNYA
Tenaya Therapeutics — Investor Presentation (September 2026)
34 slides from Tenaya Therapeutics's investor presentation, September 2026
Slide 1: Corporate Presentation
Corporate Presentation September 2026
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management’s beliefs and assumptions and on information currently availabl
Slide 3: Leading the Precision Medicine Revolution in Cardiovascular Disease
In 2026, vision becomes reality Leading the Precision Medicine Revolution in • Proof-of-concept data has the potential to Cardiovascular Disease establish registrational pathway for multiple gene therapy programs • Founded to transform the treatment of heart disease with therapeutics that target the
Slide 4: Advancing TN-201 and TN-401 towards pivotal studies
IMMEDIATE OPPORTUNITY: Advancing TN-201 and TN-401 towards pivotal studies Large market potential in Early evidence of clinically Multiple de-risking Regulatory progress rare disease setting meaningful benefit catalysts in 2026 across both programs Addressable populations Biopsy evidence of TN-201:
Slide 5: Advancing TN-301 towards clinical proof-of-activity
NEXT OPPORTUNITY: Advancing TN-301 towards clinical proof-of-activity to unlock “pipeline-in-a-pill” potential Broad utility demonstrated by Tenaya and others Mechanism of HDAC6 inhibition well understood DECREASES INCREASES • Inflammation • Autophagy • Oxidative stress • Lipid metabolism • Fibrosis
Slide 6: Diverse clinical stage programs supported by innovation engine
Diverse clinical stage programs supported by innovation engine CLINICAL-STAGE PIPELINE Program Modality Epidemiology Research Preclinical Phase 1b/2 TN-201 AAV9 gene therapy 120K (US) MYBPC3+ HCM TN-401 AAV9 gene therapy 75K (US) PKP2+ ARVC TN-301 Prevalent & HFpEF/cardiac, muscular Small Molecule R
Slide 7: TN-201 for MYBPC3-associated HCM
TN-201 for MYBPC3-associated HCM
Slide 8: MYBPC3-associated HCM is estimated to affect 120,000 people in the U.S.
MYBPC3-associated HCM is estimated to affect 120,000 people in the U.S. alone1 A severe and progressive autosomal dominant condition affecting adults, teens, children and infants GABE | AGE 10 HCM HEART Living with MYBPC3+ HCM Thickened left ventricle ~57% of identified genetic variants underlying f
Slide 9: TN-201 is the first gene therapy being developed for MYBPC3-associated HCM
TN-201 is the first gene therapy being developed for MYBPC3-associated HCM1 MYBPC3 Pathophysiology TN-201 Mechanism of Action TN-201 cassette AAV9 capsid Heterozygous mutations in the TN-201 delivers a full-length, functional copy of the MYBPC3 gene to MYBPC3 gene lead to significantly cardiomyocyte
Slide 10: MyPEAK-1 at-a-glance: Seeking directional consistency across multiple parameters
MyPEAK-1 at-a-glance: Seeking directional consistency across multiple parameters MyPEAK-1 Phase 1b/2 clinical trial Positive interim results1 show evidence of clinical benefit Designed to assess safety, tolerability and dose Multiple parameters of disease improving across all six evaluable patients
Slide 11: Decreases in hypertrophy suggest cardiac remodeling and compare favorably with CMIs
Decreases in hypertrophy suggest cardiac remodeling and compare favorably with CMIs All MyPEAK-1 patients achieved TN-201 decreases across multiple Change from baseline to most recent visit reductions in LVMI measures of hypertrophy vs. CMIs* (g/m2) Left ventricular mass index Relative change from b
Slide 12: Symptom burden reduced in all patients by at least one measure
Symptom burden reduced in all patients by at least one measure following TN-201 treatment 83% of MyPEAK-1 patients Cohort 1 achieved 67% achieved meaningful improvements in NYHA class I (asymptomatic) status KCCQ Clinical Summary Score2 New York Heart Association Classification change KCCQ-CSS chang
Slide 13: Functional improvements observed for a majority of Cohort 2 patients
Functional improvements observed for a majority of Cohort 2 patients Two of three of Cohort Six-minute Walk2Test patients achieved improvements in at least one of two validated measurements of exercise capacity Six-minute walk test from baseline to MRV Change in peakVO2 from baseline to MRV Measured
Slide 14: TN-201 is being expressed in cardiomyocytes and is generally well tolerated
TN-201 is being expressed in cardiomyocytes and is generally well tolerated Totality of biopsy data show TN-201 is TN-201 has been well tolerated Change from baseline to most recent visit achieving transduction and expression at both (g/mdoses 2) AEs associated with TN-201 treatment were mild, trans
Slide 15: TN-201 intended to treat the full spectrum of MYBPC3-associated HCM
TN-201 intended to treat the full spectrum of MYBPC3-associated HCM Total TN-201 potential Those <18yo suffer the Addressable HCM populations in the U.S. opportunity greatest unmet need HCM prevalence is growing MYBPC3 variants account for driven by increasing 20% of all HCM cases3 diagnosis and agi
Slide 16: Children with MYBPC3+ disease are at heightened risk
Children with MYBPC3+ disease are at heightened risk for heart failure, arrhythmias, hospitalizations and death1 The unmet need in pediatric patients Genotype status impacts outcomes1 >90% of patients in MyClimb have non-obstructive HCM1 HOMOZYGOUS: 36% more likely to develop life-threatening ventri
Slide 17: TN-401 for PKP2-associated ARVC
TN-401 for PKP2-associated ARVC CONFIDENTIAL
Slide 18: PKP2-associated ARVC is estimated to affect >70,000 people in the U.S.
PKP2-associated ARVC is estimated to affect >70,000 people in the U.S.1 ARVC is a severe and progressive genetic heart TRACY | AGE 45 disease lacking therapeutic treatment options Living with PKP2+ ARVC ARVC HEART Unstable connections and scar tissue >15% of heart-related deaths in patients < 35 are
Slide 19: TN-401 gene therapy for PKP2-associated ARVC
TN-401 gene therapy for PKP2-associated ARVC PKP2+ Pathophysiology TN-401 Mechanism of Action Treated with TN-401 Desmosome and Gap Junctions in PKP2-associated ARVC Heart PKP2 Missing TN-401 PKP2 cassette protein AAV9 capsid Desmosome structural Desmosome integrity structure in restored disarray Ga
Slide 20: RIDGE-1 at-a-glance: Aiming to reduce arrhythmic events
RIDGE-1 at-a-glance: Aiming to reduce arrhythmic events Strong early evidence of improved RIDGE-1 Phase 1/2 clinical trial electrical stability in all patients Designed to assess safety, tolerability and dose • All evaluable patients saw measurable improvements in arrhythmia burden • Measures of RV
Slide 21: Consistent reductions in PVC burden achieved in all patients post-TN-401
Consistent reductions in PVC burden achieved in all patients post-TN-401 64% mean reduction in daily PVC count across all patients as measured by continuous ECG over 7-day period Change in Daily PVC Rate from Screening to Most Recent Visit Cohort 1 Average = 60% Reduction Cohort 2 Average = 67% Redu
Slide 22: Patients with high NSVT burden had dramatic reductions over time
Patients with high NSVT burden had dramatic reductions over time Patients 2 and 5 saw major declines in daily NSVT burden, while other patients maintained low and stable rates Change in Daily PVC Rate from Screening to Most Recent Visit Cohort 1 (3E13 vg/kg) Cohort 2 (6E13 vg/kg) Patient 1 Patient 2
Slide 23: PVC and NSVT burden are key indicators of electrical instability
PVC and NSVT burden are key indicators of electrical instability and risk of life-threatening events Frequency Severity PVCs NSVTs SVTs VFs SCA Premature Ventricular Non-Sustained Sustained Ventricular Ventricular Sudden Cardiac Contractions Ventricular Tachycardias Tachycardias Fibrillations Arrest
Slide 24: PKP2 is being expressed in cells and TN-401 is generally well tolerated
PKP2 is being expressed in cells and TN-401 is generally well tolerated at both doses Biopsy data support TN-401 TN-401 well tolerated at both doses pharmacodynamic effect • Mean TN-401 DNA levels were 3.4 vg/dg (Cohort 1) and 3.8 Majority of TN-401-related AEs were mild, vg/dg (Cohort 2) asymptomat
Slide 25: RIDGE the largest natural history study of PKP2+ ARVC in the world
RIDGE the largest natural history study of PKP2+ ARVC in the world Largest Ever PKP2+ ARVC …Collecting Data …Directly Feeding Natural History Study… Across Domains… RIDGE-1 Trial • All RIDGE-1 participants to date were identified through RIDGE >185 >2,500 Years of • RIDGE informed RIDGE-1 design, Pa
Slide 26: TN-301 HDAC6 Inhibitor
7’ TENAYA THERAPEUTICS TN-301 HDAC6 Inhibitor
Slide 27: Growing conviction in TN-301 opportunity supported by external data
Growing conviction in TN-301 opportunity supported by external preclinical and clinical data Tenaya has extensively studied HDAC6 inhibition multi-modal Clinical results with pan-HDAC HDAC6 inhibition MOA externally validated inhibition de-risks TN-301 Preclinical validation achieved in HDAC6 inhibi
Slide 28: Tenaya's HDAC6 inhibitors offer distinct advantages
Tenaya’s HDAC6 inhibitors offer distinct advantages HDACs are enzymes that regulate cellular Tenaya’s HDAC6 inhibitors have ≥3500x processes and gene expression selectivity for HDAC6 vs. other HDACs HDAC6 • Highly specific: ≥3500x selectivity for HDAC6 HDACs TYA-018 HDAC6 is a vs. other HDAC • H
Slide 29: TN-301 demonstrates superior activity vs. commercially available therapeutics
TN-301 demonstrates superior activity vs. commercially available therapeutics in validated disease models HFpEF: Tn-301 improves diastole alone or in DMD: Potential to improve skeletal and cardiac Change from baseline to most recent visit combination with SGLT2 inhibitors muscle deficits with greate
Slide 30: TN-301 Phase 1 trial results in healthy participants
TN-301 Phase 1 trial results in healthy participants TN-301 was TN-301 was generally well well toleratedacross tolerated at all doses broadtested; dose ranges AEs reported were mild and occurred with similar frequency to those in placebo arm • Phase 1 evaluated single-ascending doses of 1mg–700mg an
Slide 31: Key Milestones & Financials
Key Milestones & Financials CONFIDENTIAL
Slide 32: Anticipated program milestones
Anticipated program milestones TN-201 for MYBPC3-associated HCM • Q4’26: Share longer-term results from • Reported Cohort 1 & 2 MyPEAK-1 data MyPEAK-1 • Competed enrollment in MyPEAK-1 • Q4’26: Provide update on pivotal trial plan discussions with regulators TN-401 for PKP2-associated ARVC • Q4’26:
Slide 33: Cash and shares outstanding
Cash and shares outstanding $78.1M cash as of June 30, 2026 1 Expected runway through Q3 2027 Number of shares (M) Common stock2 Shares outstanding 224.2 March 2025 warrants3 Exercise price of $0.80 per share, expire March 2030 75.0 December 2025 warrants4 Exercise price of $1.50 per share, expire D
Slide 34: Thank you
Thank you & SS a VAN GAN THERAPEUTICS T
Tenaya Therapeutics — Investor Presentation (September 2026) on 6ix